Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

August 28, 2012; 79 (9) Global Perspectives

Reportable neurologic diseases in refugee camps in 19 countries

Farrah J. Mateen, Marco Carone, Christopher Haskew, Paul Spiegel
First published August 27, 2012, DOI: https://doi.org/10.1212/WNL.0b013e318266fcf1
Farrah J. Mateen
From the Department of Neurology (F.J.M.), the Johns Hopkins Hospital, Baltimore; Department of International Health (F.J.M.), the Bloomberg School of Public Health, Baltimore, MD; Division of Biostatistics (M.C.), School of Public Health, University of California, Berkeley; and United Nations High Commissioner for Refugees (C.H., P.S.), Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Carone
From the Department of Neurology (F.J.M.), the Johns Hopkins Hospital, Baltimore; Department of International Health (F.J.M.), the Bloomberg School of Public Health, Baltimore, MD; Division of Biostatistics (M.C.), School of Public Health, University of California, Berkeley; and United Nations High Commissioner for Refugees (C.H., P.S.), Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Haskew
From the Department of Neurology (F.J.M.), the Johns Hopkins Hospital, Baltimore; Department of International Health (F.J.M.), the Bloomberg School of Public Health, Baltimore, MD; Division of Biostatistics (M.C.), School of Public Health, University of California, Berkeley; and United Nations High Commissioner for Refugees (C.H., P.S.), Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Spiegel
From the Department of Neurology (F.J.M.), the Johns Hopkins Hospital, Baltimore; Department of International Health (F.J.M.), the Bloomberg School of Public Health, Baltimore, MD; Division of Biostatistics (M.C.), School of Public Health, University of California, Berkeley; and United Nations High Commissioner for Refugees (C.H., P.S.), Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Reportable neurologic diseases in refugee camps in 19 countries
Farrah J. Mateen, Marco Carone, Christopher Haskew, Paul Spiegel
Neurology Aug 2012, 79 (9) 937-940; DOI: 10.1212/WNL.0b013e318266fcf1

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
649

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Background: Approximately one-third of refugees worldwide live in refugee camps. Selected neurologic diseases are actively reported in some refugee camps.

Methods: The United Nations High Commissioner for Refugees monitors health visits in refugee camps with the assistance of more than 25 partner organizations using standardized case definitions. Neurologic diseases were selected and searched for the years 2008 to 2011. The number of health care visits for a neurologic disease was calculated and divided by the aggregated number of reporting months available for each refugee camp (“visits per camp-month”).

Results: Five neurologic diseases were reported from 127 refugee camps in 19 countries. Visits for chronic, noncommunicable diseases including epilepsy (53,941 visits in 1,426 camp-months, 48% female) and cerebrovascular disease (4,028 visits in 1,333 camp-months, 51% female) far exceeded those for neurologic infectious diseases (acute flaccid paralysis/poliomyelitis, 78 visits in 3,816 camp-months, 42% female; leprosy, 74 visits in 3,816 camp-months, 66% female; meningitis, 477 visits in 3,816 camp-months, 51% female). In 2011, these diseases accounted for 31,349 visits globally with 91% of visits for epilepsy.

Conclusions: Targeted programs addressing epilepsy and stroke among refugees in camps should become a priority and indicate that other chronic neurologic diseases that may be under- or misdiagnosed may also be common in refugee camps. Given that significant under-reporting is likely, our findings demonstrate the pressing need for coordinated preventive and interventional measures for epilepsy and stroke in refugee camps.

GLOSSARY

UNHCR=
United Nations High Commissioner for Refugees;
webHIS=
Web-based Health Information System

Approximately 30% of refugees lived in refugee camps in 2010, including 52% of children and 49% of women.1 Refugee camps are meant to be temporary locations for shelter and emergency aid provision, usually established by governments or international agencies in response to natural disaster, famine, political discord, or armed conflict. Although not recognized as a durable solution, refugee camps may be the home of entire generations of refugees and reach populations of more than 100,000 people per camp.1

Limited information is available on neurologic diseases in refugee camps, and is mainly focused on meningococcal meningitis outbreaks during the 1990s.2,–,5 Compiled surveillance data would be valuable for setting health care policy related to the prevention, management, and reduction of neurologic diseases in refugee camps on a global basis. Here, we present the burden of health care visits per reportable neurologic disease by country level from refugee camps supported by the United Nations High Commissioner for Refugees (UNHCR).

METHODS

Data reporting and collection.

The UNHCR Web-based Health Information System (webHIS) is a standardized reporting tool designed to monitor the health status of refugees and other persons of concern to the UNHCR. Selected reportable diseases are monitored when they have the potential to affect refugees in high numbers or lead to important interventions. Data are collected at each camp by UNHCR employees and other aid workers on a weekly basis, involving 25 implementing organizations worldwide, using case definitions (table 1). Approximately 1.6 million displaced persons are covered by camps participating in the webHIS. Visit data are collected via a standardized online reporting form, downloaded at the refugee camp site, and deposited electronically each month. Not all refugee camps report on all reportable neurologic diseases every month. For each month, the number of camps reporting on the disease of interest was calculated. The tallies were then summed over months and used to standardize the reporting counts of specific diseases, yielding per camp-month visit rates. This standardization allowed counts to be compared across various strata (e.g., sex, reporting years).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1

Overview of reportable neurologic disease visits to the UNHCR (2008–2011)

For each health visit, patient sex, location, and month of encounter were reported. Neurologic diseases were searched among all reportable diseases in webHIS during the study timeframe (January 1, 2008–December 31, 2011 for acute flaccid paralysis, leprosy, and meningitis; July 1, 2009–December 31, 2011 for cerebrovascular disease and epilepsy). Camp level information is available at https://unhcr.org/his. Use of deidentified programmatic data used in this study was approved by The Johns Hopkins University Institutional Review Board.

RESULTS

Participating countries were from 3 World Health Organization–defined regions: African (93 refugee camps in 13 countries: Burundi, Cameroon, Central African Republic, Chad, Democratic Republic of Congo, Ethiopia, Guinea, Kenya, Namibia, Rwanda, Tanzania, Uganda, Zambia), Eastern Mediterranean (14 refugee camps in 3 countries: Djibouti, Sudan, Yemen), and Southeast Asian (20 camps in 3 countries: Bangladesh, Nepal, Thailand). The countries with the highest number of reporting camps were Chad (n = 28), Ethiopia (n = 13), Uganda (n = 11), Sudan (n = 10), and Cameroon (n = 10). Reporting of epilepsy and cerebrovascular disease began in July 2009 and was available in 14 countries for cerebrovascular diseases and 16 countries for epilepsy (table 2).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2

Location and burden of neurologic disease visits by country for refugee camps reporting to UNHCR webHIS (2008–2011)

There were 5 reported neurologic diseases in the webHIS of the UNHCR. In 2011, these diseases accounted for 31,349 visits globally of which 91% were for epilepsy. The age distribution of the 53,941 health visits for epilepsy for all years reported was as follows: <5 years old (n = 3,964 visits, 7.3%), 5–17 years old (n = 22,736 visits, 42.1%), 18–59 years old (n = 22,489 visits, 41.7%), and >60 years old (n = 719 visits, 1.3%). Age information was unavailable for 4,038 visits (7.5%). Table 1 compares the reported health visit utilization of neurologic disease, standardized by number of reporting months available.

DISCUSSION

The UNHCR webHIS demonstrates feasibility of an active reporting system for key neurologic diseases in refugee camps on a global basis. WebHIS depends on the skills of nonphysician health care workers to report on neurologic diseases to monitor disease outbreaks, reveal health utilization trends, and develop broad estimates of the burden of disease. To date, most reported neurologic diseases of interest to UNHCR have been infectious in nature. However, these results suggest that infectious neurologic diseases are much less common than epilepsy and stroke.

The recent inclusion of stroke and epilepsy on reporting forms will be crucial for future humanitarian crises. Epilepsy represents more than 9 out of every 10 visits for reportable neurologic diseases in refugee camps. The underlying causes of epilepsy and seizures in refugee camps are unknown, but likely represent similar risk factors to other inhabitants in the same region, including perinatal injury and birth defects, febrile seizures, head trauma, genetic diseases, cerebral malaria, previous stroke, and related causes. The overall aging population and existence of affordable medications on the WHO Essential List of Medicines should lead to more precise and field-tested case definitions for neurologic diseases among refugees in camps, including studies focusing on different age groups. It is not reported whether cases were treated or untreated. If, however, each health visit for epilepsy represented one individual who required antiepileptic drug treatment, the cost of phenobarbital to treat all refugees would be relatively small. Given a median defined daily dose of phenobarbital of 100 mg, the cost to treat all refugees with epilepsy in camps would be approximately $270,000 USD (estimated approximately $5 USD per person per year).

Monitoring of meningitis in sub-Saharan Africa is an important way to avoid epidemic outbreaks due to Neisseria meningitidis. Although likely under-reported here, the overall low counts of meningitis should be considered as a success of surveillance, treatment, and recent vaccination campaigns. In Goma, Democratic Republic of Congo (former Zaire) in 1994, recovery rates from meningococcal meningitis treated with IV penicillin and chloramphenicol in a field hospital were comparable to rates found in advanced medical facilities.2 Early vaccination against meningococcal meningitis in a refugee camp of Sudanese nationals in northern Uganda led to less deaths compared to a camp where vaccination was delayed.3 Simple, reliable surveillance systems for meningitis have been advocated for more than 20 years4; however, even when implemented, important infectious disease outbreaks can be missed. The eventual inclusion of dementia, traumatic head and spinal cord injury, cerebral palsy, and chronic pain will also be important in the surveillance of neurologic diseases in future humanitarian crisis settings; this will require further training of medical staff on diagnosis and treatment.

We recognize important limitations to reporting data from the webHIS. Data are reported for each visit rather than for each refugee. The population structure of refugee camps is not static. Therefore, incidence and prevalence estimates of disease by country and camp level cannot be made. Data were entered based on standard case definitions and were not verified by physicians in many cases. Cases of meningitis were unlikely to have had routine CSF confirmation, and others may not have reached medical attention. Cerebral malaria and multiple other neurologic diseases of importance to refugees may not be reported because of a lack of training and limited monitoring of implementation of individual reporting categories. Therefore, it is assumed that there is significant under-reporting and risk of misclassification of most neurologic diseases.

However, given the available evidence, there is a growing need for guidelines for the prevention, evaluation, and care of refugees with neurologic diseases. This includes better coordination of information and action through roll-out programs for aspirin, antihypertensive medications, phenobarbital, phenytoin, analgesics, and potentially other antiepileptic drugs and levodopa. Since refugee camps often have better reporting capacity and treatment availability than for populations in the host country, attention to the neurologic health of refugees can advance care in the larger geographic regions where camps exist.

AUTHOR CONTRIBUTIONS

Dr. Mateen was involved with data interpretation, data analysis, writing, and editing of the manuscript. Dr. Carone was involved with data interpretation, data analysis, writing, and editing of the manuscript. Dr. Haskew was involved with data acquisition, data interpretation, and editing of the manuscript. Dr. Spiegel was involved with data acquisition, data interpretation, and editing of the manuscript.

DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Footnotes

  • Study funding: Dr. Mateen is supported by the American Academy of Neurology Practice Research Fellowship Grant.

  • Copyright © 2012 by AAN Enterprises, Inc.

REFERENCES

  1. 1.↵
    United Nations High Commissioner for Refugees. UNHCR Global Trends 2010. Available at: at http://www.unhcr.org/4dfa11499.html. Accessed March 4, 2012.
  2. 2.↵
    1. Haelterman E,
    2. Boelaert M,
    3. Suetens C,
    4. Blok L,
    5. Henkens M,
    6. Toole MJ
    . Impact of a mass vaccination campaign against a meningitis epidemic in a refugee camp. Trop Med Int Health 1996;1:385–392.
    OpenUrlPubMed
  3. 3.↵
    1. Santaniello-Newton A,
    2. Hunter PR
    . Management of an outbreak of meningococcal meningitis in a Sudanese refugee camp in Northern Uganda. Epidemiol Infect 2000;124:75–81.
    OpenUrlPubMed
  4. 4.↵
    1. Moore PS,
    2. Toole MJ,
    3. Nieburg P,
    4. Waldman RJ,
    5. Broome CV
    . Surveillance and control of meningococcal meningitis epidemics in refugee populations. Bull World Health Organ 1990;68:587–596.
    OpenUrlPubMed
  5. 5.↵
    1. Mateen FJ
    . Neurological diseases in complex humanitarian emergencies and natural disasters. Ann Neurol 2010;68:282–294.
    OpenUrlPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • METHODS
    • RESULTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Topics Discussed

  • All Health Services Research
  • All Epilepsy/Seizures
  • All epidemiology
  • Meningitis

Alert Me

  • Alert me when eletters are published
Neurology: 99 (1)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise